Loss Narrows. Kestra Medical Technologies (NASDAQ: KMTS) reported a loss of $0.61 per share for Q3 fiscal 2026, missing consensus estimates. The medical device maker posted a net loss of $34.2 million on revenue of $24.6 million. Year-over-year, the loss widened from a loss of $0.36 per share in Q3 2025.
Revenue accelerates sharply. Revenue of $24.6 million topped the $22.9 million consensus estimates, marking a 62.7% surge from $15.1 million in the year-ago quarter. The company generated gross profit of $12.9 million against a cost of revenue of $11.6 million, yielding a 52.5% gross margin. Operating loss reached $34.8 million, while adjusted EBITDA came in at negative $21.2 million. The revenue beat extends a pattern of top-line outperformance.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.